Buffer system and corresponding liquid preparation and application thereof

CN119015447APending Publication Date: 2024-11-26KANGLIN BIOTECHNOLOGY (HANGZHOU) CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411191991.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-09-01
Filing Date
2024-08-28
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The poor stability of AAV gene therapy vectors during production, storage and administration leads to a decrease in transduction efficiency and triggers adverse reactions during high dose systemic administration. The high osmotic pressure of existing preparations leads to an immune response, limiting its clinical application.

Method used

Develop a buffer system, including soluble salts, polyols and pH buffers, adjust the pH value of the solution between 7.0 and 8.0, reduce the osmotic pressure, prevent damage to virus particles during low temperature and freeze-thawing, and improve their stability. and dispersibility.

Benefits of technology

It significantly improves the stability and dispersion of AAV particles, reduces the aggregate content and free nucleic acid content, avoids adverse reactions caused by high osmotic pressure, expands its application scenarios, and ensures stability and safety under isosmotic pressure. sex.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015447A_ABST
    Figure CN119015447A_ABST
Patent Text Reader

Abstract

The invention relates to a buffer system for improving the stability and dispersity of virus particles and a corresponding liquid preparation and application thereof, in particular, the buffer system comprises soluble salt substances, polyhydric alcohols and a pH buffer solution, and the preparation comprises a therapeutically effective amount of virus particles and the buffer system. According to the buffer system disclosed by the invention, the stability and dispersity of the virus particles can be obviously improved, the aggregate content and the free nucleic acid content are reduced, the signal response intensity of the virus particles is not obviously reduced, the virus activity is not obviously reduced, and the dispersion quantity and stability of the virus particles can be obviously improved (such as enhanced).
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Nucleic acid construct for treating hereditary coagulation factor deficiency disease and application of nucleic acid construct

    CN117247973A

  • Nucleic acid constructs and uses thereof

    CN117363656A

  • Formulations of highly purified viral particles

    CN116323925A

  • Soluble thrombomodulin-containing composition

    JP2000026309A

  • Improved pharmaceutical compositions containing adeno-associated viral vector

    WO2022133324A1